128 related articles for article (PubMed ID: 38648662)
1. Therapeutic Drug Monitoring of Intravenous Busulfan and Analytical Challenges due to the Drug Formulation Excipient PEG 400: Letter to the Editor.
Vethe NT; Andersen AM; Gedde-Dahl T; Büchner J; Bergan S
Ther Drug Monit; 2024 Jun; 46(3):416-417. PubMed ID: 38648662
[No Abstract] [Full Text] [Related]
2. PEG 400 Ion Suppression in Busulfan Detection by High-Performance Liquid Chromatography-Tandem Mass Spectrometry.
De Gregori S; Capone M; De Silvestri A; Albertini R
Ther Drug Monit; 2024 Jun; 46(3):417. PubMed ID: 38723116
[No Abstract] [Full Text] [Related]
3. Dose individualization of intravenous busulfan in pediatric patients undergoing bone marrow transplantation: impact and in vitro evaluation of infusion lag-time.
Neroutsos E; Athanasiadou I; Paisiou A; Zisaki K; Goussetis E; Archontaki H; Tsirigotis P; Kitra M; Grafakos S; Spyridonidis A; Dokoumetzidis A; Valsami G
J Pharm Pharmacol; 2021 Sep; 73(10):1340-1350. PubMed ID: 34244783
[TBL] [Abstract][Full Text] [Related]
4. Pretransplant conditioning in adults and children: dose assurance with intravenous busulfan.
Fisher VL; Barnes YJ; Nuss SL
Oncol Nurs Forum; 2006 Nov; 33(2):E36-43. PubMed ID: 16518436
[TBL] [Abstract][Full Text] [Related]
5. PEG 400 Ion Suppression in Busulfan Detection by High-Performance Liquid Chromatography-Tandem Mass Spectrometry.
De Gregori S; Capone M; De Silvestri A; Albertini R
Ther Drug Monit; 2023 Dec; 45(6):827-831. PubMed ID: 37684724
[TBL] [Abstract][Full Text] [Related]
6. Variation in prescribing patterns and therapeutic drug monitoring of intravenous busulfan in pediatric hematopoietic cell transplant recipients.
McCune JS; Baker KS; Blough DK; Gamis A; Bemer MJ; Kelton-Rehkopf MC; Winter L; Barrett JS
J Clin Pharmacol; 2013 Mar; 53(3):264-75. PubMed ID: 23444282
[TBL] [Abstract][Full Text] [Related]
7. Busulfan systemic exposure after oral administration of extemporeanously prepared high-dose busulfan capsules.
Kolbe K; Karstens A; Krämer I
J Oncol Pharm Pract; 2010 Sep; 16(3):151-9. PubMed ID: 19759052
[TBL] [Abstract][Full Text] [Related]
8. An automated method for supporting busulfan therapeutic drug monitoring.
Juenke JM; Miller KA; McMillin GA; Johnson-Davis KL
Ther Drug Monit; 2011 Jun; 33(3):315-20. PubMed ID: 21544019
[TBL] [Abstract][Full Text] [Related]
9. Development and characterization of an organic solvent free, proliposomal formulation of Busulfan using quality by design approach.
Chobisa D; Patel K; Monpara J; Patel M; Vavia P
Int J Pharm; 2018 Jan; 535(1-2):360-370. PubMed ID: 29126906
[TBL] [Abstract][Full Text] [Related]
10. Limited Sampling Strategies Supporting Individualized Dose Adjustment of Intravenous Busulfan in Children and Young Adults.
Teitelbaum Z; Nassar L; Scherb I; Fink D; Ring G; Lurie Y; Krivoy N; Bentur Y; Efrati E; Kurnik D
Ther Drug Monit; 2020 Jun; 42(3):427-434. PubMed ID: 31479045
[TBL] [Abstract][Full Text] [Related]
11. Accurate Prediction of Initial Busulfan Exposure Using a Test Dose With 2- and 6-Hour Blood Sampling in Adult Patients Receiving a Twice-Daily Intravenous Busulfan-Based Conditioning Regimen.
Huang J; Li Z; Liang W; Chen B; Hu J; Yang W
J Clin Pharmacol; 2019 May; 59(5):638-645. PubMed ID: 30512187
[TBL] [Abstract][Full Text] [Related]
12. Test Dose Pharmacokinetics in Pediatric Patients Receiving Once-Daily IV Busulfan Conditioning for Hematopoietic Stem Cell Transplant: A Reliable Approach?
Brooks KM; Jarosinski P; Hughes T; Kang E; Shah NN; Gall JBL; Hickstein DD; De Ravin SS; George JM; Kumar P
J Clin Pharmacol; 2018 Mar; 58(3):332-339. PubMed ID: 29238995
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic drug monitoring is essential for intravenous busulfan therapy in pediatric hematopoietic stem cell recipients.
Malär R; Sjöö F; Rentsch K; Hassan M; Güngör T
Pediatr Transplant; 2011 Sep; 15(6):580-8. PubMed ID: 21736681
[TBL] [Abstract][Full Text] [Related]
14. Population Pharmacokinetics of Intravenous Busulfan in Japanese Pediatric Patients With Primary Immunodeficiency Diseases.
Ishiwata Y; Nagata M; Tsuge K; Takahashi H; Suzuki S; Imai K; Takagi M; Kanegane H; Morio T; Yasuhara M
J Clin Pharmacol; 2018 Mar; 58(3):327-331. PubMed ID: 29077206
[No Abstract] [Full Text] [Related]
15. Comparison of Two Analytical Methods for Busulfan Therapeutic Drug Monitoring.
De Gregori S; Tinelli C; Manzoni F; Bartoli A
Eur J Drug Metab Pharmacokinet; 2021 Jan; 46(1):155-159. PubMed ID: 33231835
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of two software using Bayesian methods for monitoring exposure and dosing once-daily intravenous busulfan in paediatric patients receiving haematopoietic stem cell transplantation.
Lawson R; Paterson L; Fraser CJ; Hennig S
Cancer Chemother Pharmacol; 2021 Sep; 88(3):379-391. PubMed ID: 34021809
[TBL] [Abstract][Full Text] [Related]
17. A limited sampling strategy for pharmacokinetic directed therapy with intravenous busulfan.
Vaughan WP; Carey D; Perry S; Westfall AO; Salzman DE
Biol Blood Marrow Transplant; 2002; 8(11):619-24. PubMed ID: 12463481
[TBL] [Abstract][Full Text] [Related]
18. Intravenous busulfan dose individualization - impact of modeling approach on dose recommendation.
Abdel-Rahman SM; Casey KL; Garg U; Dalal J
Pediatr Transplant; 2016 May; 20(3):443-8. PubMed ID: 26854326
[TBL] [Abstract][Full Text] [Related]
19. Acute safety and pharmacokinetics of intravenous busulfan when used with oral busulfan and cyclophosphamide as pretransplantation conditioning therapy: a phase I study.
Andersson BS; Madden T; Tran HT; Hu WW; Blume KG; Chow DS; Champlin RE; Vaughan WP
Biol Blood Marrow Transplant; 2000; 6(5A):548-54. PubMed ID: 11071260
[TBL] [Abstract][Full Text] [Related]
20. Pharmacometabonomic Prediction of Busulfan Clearance in Hematopoetic Cell Transplant Recipients.
Navarro SL; Randolph TW; Shireman LM; Raftery D; McCune JS
J Proteome Res; 2016 Aug; 15(8):2802-11. PubMed ID: 27350098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
